DFSV vs XBI
Dimensional US Small Cap Value ETF vs SPDR S&P Biotech ETF
- • DFSV has the lower expense ratio at 0.30% vs 0.35% for XBI.
- • DFSV pays a higher dividend yield (1.43%).
Side-by-side metrics
| Metric | DFSV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.30% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.43% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $7.51B | $8.30B |
YTD return | 15.46% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.10 | 1.09 |
P/E ratio | 14.28 | — |
Last price | $37.46 | $133.66 |
Inception | — | — |
Issuer | Dimensional | State Street |
DFSV top holdings
| DINO | HF Sinclair Corp | 0.81% |
| OVV | Ovintiv Inc | 0.80% |
| APA | APA Corp | 0.77% |
| BWA | BorgWarner Inc | 0.76% |
| IVZ | Invesco Ltd | 0.75% |
| WCC | WESCO International Inc | 0.72% |
| KNX | Knight-Swift Transportation Holdings Inc Class A | 0.71% |
| WBS | Webster Financial Corp | 0.67% |
| AMKR | Amkor Technology Inc | 0.65% |
| DAR | Darling Ingredients Inc | 0.65% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About DFSV
DFSV (Dimensional US Small Cap Value ETF) is Systematic small-cap value strategy from Dimensional. Managed by Dimensional, the fund carries $7.5B in assets under management, an expense ratio of 0.30%, a dividend yield of 1.43%. Its largest holding is HF Sinclair Corp (DINO), which represents 0.8% of the portfolio. Real Estate is the fund's largest sector exposure at 0.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.